Title |
Phase 1 Study of the Effect of Icosapent Ethyl on Warfarin Pharmacokinetic and Anticoagulation Parameters
|
---|---|
Published in |
Clinical Drug Investigation, April 2014
|
DOI | 10.1007/s40261-014-0194-1 |
Pubmed ID | |
Authors |
Rene A. Braeckman, William G. Stirtan, Paresh N. Soni |
Abstract |
Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester approved to reduce triglyceride levels in patients with severe (≥5.65 mmol/L) hypertriglyceridemia. EPA, the active metabolite of IPE, is mainly metabolized via β-oxidation, and studies suggest that omega-3 fatty acids such as EPA may have antithrombotic effects. The objective of this study was to evaluate the effect of IPE on the pharmacokinetic and anticoagulation pharmacodynamics of warfarin, a substrate of cytochrome P450 2C9-mediated metabolism. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 3 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 31 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 8 | 26% |
Researcher | 6 | 19% |
Student > Bachelor | 4 | 13% |
Student > Ph. D. Student | 3 | 10% |
Student > Postgraduate | 3 | 10% |
Other | 1 | 3% |
Unknown | 6 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 12 | 39% |
Biochemistry, Genetics and Molecular Biology | 4 | 13% |
Nursing and Health Professions | 3 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
Agricultural and Biological Sciences | 2 | 6% |
Other | 1 | 3% |
Unknown | 7 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 February 2016.
All research outputs
#5,591,247
of 22,757,541 outputs
Outputs from Clinical Drug Investigation
#192
of 959 outputs
Outputs of similar age
#52,282
of 227,005 outputs
Outputs of similar age from Clinical Drug Investigation
#2
of 9 outputs
Altmetric has tracked 22,757,541 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 959 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 227,005 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 7 of them.